logo
  

ResMed Profit Rises

ResMed Inc (RMD) Thursday reported third-quarter net earnings of $83.3 million or $0.58 per share compared with $80.9 million or $0.56 per share last year.

Revenues for the quarter were up 6% at $380.4 million compared with $357.7 million in the prior year.

Analysts polled by Thomson Reuters estimated earnings of $0.58 per share on revenues of $374.8 million for the quarter. Analysts' estimates typically exclude special items.

"We had a successful start to fiscal year 2015, as new product launches drove revenue growth," said Mick Farrell, ResMed's chief executive officer. "Our results showed very strong performance from our European and Asia Pacific regions, as well as solid growth in the Americas."

ResMed declared a quarterly dividend of $0.28 per share.

ResMed makes medical equipment for treating managing sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lincoln Park, New Jersey -based ConSup North America Inc. is recalling around 85,984 pounds of ready-to-eat or RTE sliced prosciutto ham product produced in Germany without the benefit of equivalent inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and...

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT